PR Newswire
22 Aug 2022, 22 GMT+10
Albert Wu, MD, PhD, a recognized advocate of using stem cell therapy to treat eye conditions, will advise company's development of ocular tissue rejuvenation therapeutics
MOUNTAIN VIEW, Calif., Aug. 22, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that Albert Wu, MD, PhD, will oversee its development of ophthalmic therapeutic products as an advisor to the company.
A board-certified ophthalmologist and fellowship-trained specialist in oculoplastic and orbital surgery, Wu's academic work has focused on developing treatments for vision loss and eye disease.
At Turn Bio, he will shepherd work on TRN-004, a formulation to rejuvenate ocular tissues, including corneal, limbal and conjunctival epithelial cells, as well as corneal endothelial cells. Preclinical results show the formulation reduces inflammation, oxidative stress, and cell senescence.
TRN-004 is a tailored protein cocktail to rejuvenate targeted cells in the eye. It is produced using Turn Bio's unique mRNA-based ERA (Epigenetic Reprogramming of Aging) platform.
"Albert's life mission is to transform ophthalmology by making regenerative medicine an accepted treatment for people worldwide suffering from diseases of the eye," said Anja Krammer, the company's CEO. "His vision and experience will help us redefine how eye doctors treat age-related vision conditions for which no real cure exists."
Wu has nearly two decades of experience with ophthalmology and cellular biology. He has been honored by the National Institutes of Health, American Society of Ophthalmic Plastic and Reconstructive Surgery, Icahn School of Medicine at Mount Sinai, the University of Washington and Yale University.
"Our work has the potential to revolutionize eye care to preserve patients' vision and, ultimately, restore it," said Wu. "The ability to produce cell rejuvenation therapies and deliver them with pinpoint accuracy offers enormous promise to millions of people around the world whose sight has been compromised by untreatable conditions."
Wu received his bachelor's degree in Molecular Biophysics and Biochemistry from Yale University, his medical degree and doctoral degree in Molecular and Cellular Biology from the University of Washington. He has co-authored 55 articles on his research discoveries and has contributed to textbooks on ophthalmology and ophthalmologic oncology. He is a frequent presenter at national and international medical conferences.
ABOUT TURN BIOTECHNOLOGIES
Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level. The company's proprietary mRNA platform technology, ERA, restores optimal gene expression by combatting the effects of aging in the epigenome. This restores the cells' ability to prevent or treat disease, heal or regenerate tissue and fight incurable chronic diseases.
The company is currently completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, as well as developing therapies for ophthalmology, osteo-arthritis and the muscular system. For more information, see www.turn.bio.
FOR MORE INFORMATION, CONTACT:
Jim Martinez, rightstorygroup
[email protected] or (312) 543-9026
SOURCE Turn Biotechnologies, Inc.
Get a daily dose of Singapore Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Singapore Star.
More InformationHONG KONG: This week, Ronson Chan, chairman of the Hong Kong Journalists Association, was sentenced to five days jail for ...
WASHINGTON D.C.: In an interview with Reuters this week, U.S. commander General Chance Saltzman said the United States Space Force ...
As it did last year, the 2023 United Nations General Assembly has been debating what role the United Nations and ...
BATON ROUGE, Louisiana: Authorities said that Greg Lawson, who fled his 1991 trial in Louisiana for attempted murder 32 years ...
OTTAWA, Canada: During a joint news conference with Ukrainian President Volodymyr Zelenskyy in Canada's capital, Ottawa, Prime Minister Justin Trudeau ...
BEIJING, China: A respected Uyghur scholar, known for her extensive work in studying Uyghur folklore and traditions, has been sentenced ...
OTTAWA, Canada: As part of its plan to capitalize on strong travel demand and deploy fuel-efficient airplanes, this week, Air ...
LONDON, UK: This week, Adidas' newest running shoes, the Adizero Adios Pro Evo 1, went on sale for US$500. Worn ...
NEW YORK, New York - U.S. stocks remained on a slippery slope on Wednesday as interest rates continued to hover ...
SAN FRANCISCO, California: In a major update that will move it closer to popular artificial intelligence (AI) assistants, such as ...
YOKOHAMA, Japan: Joining a growing number of carmakers that are shifting to electric vehicles (EV) by the end of the ...
NEW YORK, New York - There was a major bust on Wall Street on Tuesday as investors continued to fret ...